Recently, a study designed to evaluate the risk of this complication using the European spontaneous reporting system, the DAPA-KETO study (DAPAgliflozin and KETOacidosis study), demonstrated a higher reporting frequency of ketoacidosis observed with dapagliflozin than with DPP-4 inhibitors or insulin [51]. This evidence concerns the gene INS and diabetes mellitus.